Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1984 Jan;73(1):160–170. doi: 10.1172/JCI111187

Development and application of an enzyme-linked immunosorbent assay for the quantitation of alternative complement pathway activation in human serum.

J T Mayes, R D Schreiber, N R Cooper
PMCID: PMC424988  PMID: 6418767

Abstract

We have developed a new, specific, and highly sensitive enzyme-linked immunosorbent assay (ELISA) which quantitates activation of the alternative pathway in human serum, plasma, or on the surface of activators. The ELISA detects the third component of complement (C3b), proteolytic fragment of complement Factor B (Bb), and properdin (P) complex or its derivative product, C3b,P. In the method, activator-plasma mixtures, plasma containing an activated alternative pathway, or other samples are added to the wells of microtitration plates precoated with antibody to P. C3b, Bb,P or C3b,P complexes which become bound are quantitated by subsequently added, enzyme-labeled, anti-C3. The resulting hydrolysis of the chromogenic substrate is expressed as nanograms of C3b by reference to a C3 standard curve. In addition to absolute specificity for activation of the pathway because of the nature of the complex detected by the assay, the ELISA is highly sensitive and able to reproducibly detect 10-20 ng/ml of C3b,P complexes in serum. This value corresponds to 0.0015% of the C3 in serum. In a series of studies to validate the parameters of the ELISA, reactivity was found to be dependent on the presence of alternative pathway proteins, the functional integrity of the pathway, and on the presence of magnesium. Sheep erythrocytes were converted to activators by treatment with neuraminidase. By using a variety of activators, the kinetics of activation and the numbers of bound C3b molecules quantitated by the ELISA were very similar to those measured by C3b deposition. The ELISA also detected identical activation kinetics when MgEGTA-serum and a mixture of the purified alternative pathway proteins were used as sources of the pathway. ELISA reaction kinetics also correlated with the restriction index, a measure of alternative pathway-activating ability. These studies cumulatively validate the ELISA as a direct and quantitative assay for alternative pathway activation. The sensitivity of the ELISA has permitted its use to detect direct alternative pathway activation by several viruses. The ELISA has also shown that certain classical pathway activators trigger the amplification loop of the alternative pathway while others do not. In addition, stable ELISA reactive complexes appeared in the supernatant of mixtures of serum with certain, but not other activators. The ability of the ELISA to detect activation which has already occurred and the stability of the reactive complexes permits studies of clinical sera. Normal human sera (20) contained low levels (5-20 ng/ml) of ELISA-reactive complexes. A proportion of sera from individuals with the adult respiratory distress syndrome (9-10), typhoid fever (8-10), malaria (3-5), gram-negative sepsis (9 of 47), acute trauma and shock (6 f 25), and systemic lupus erythematosus (3 of 29) showed elevated levels of complexes reactive in the alternative pathway ELISA. In contrast, nine sera from patients with circulating C3 nephritic factor were not reactive in the ELISA.

Full text

PDF
160

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aguado M. T., Perrin L. H., Ramirez R., Miescher P. A., Lambert P. H. Evaluation of alternative pathway and factor B haemolytic activities in patients with systemic lupus erythematosus: correlations with the alternative pathway regulatory proteins. Clin Exp Immunol. 1980 Dec;42(3):495–505. [PMC free article] [PubMed] [Google Scholar]
  2. Arroyave C. M., Bhat K. N., Crown R. Activation of the alternative pathway of the complement system by radiographic contrast media. J Immunol. 1976 Nov;117(5 PT2):1866–1869. [PubMed] [Google Scholar]
  3. Arroyave C. M., Wilson M. R., Tan E. M. Serum factors activating the alternative complement pathway in autoimmune disease: description of two different factors from patients with systemic lupus erythematosus. J Immunol. 1976 Mar;116(3):821–826. [PubMed] [Google Scholar]
  4. Beebe D. P., Schreiber R. D., Cooper N. R. Neutralization of influenza virus by normal human sera: mechanisms involving antibody and complement. J Immunol. 1983 Mar;130(3):1317–1322. [PubMed] [Google Scholar]
  5. Bjornson A. B., Bjornson H. S., Altemeier W. A. Reduction in alternative complement pathway mediated C3 conversion following burn injury. Ann Surg. 1981 Aug;194(2):224–231. doi: 10.1097/00000658-198108000-00018. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Chapitis J., Lepow I. H. Multiple sedimenting species of properdin in human serum and interaction of purified properdin with the third component of complement. J Exp Med. 1976 Feb 1;143(2):241–257. doi: 10.1084/jem.143.2.241. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Chenoweth D. E., Cooper S. W., Hugli T. E., Stewart R. W., Blackstone E. H., Kirklin J. W. Complement activation during cardiopulmonary bypass: evidence for generation of C3a and C5a anaphylatoxins. N Engl J Med. 1981 Feb 26;304(9):497–503. doi: 10.1056/NEJM198102263040901. [DOI] [PubMed] [Google Scholar]
  8. Cooper N. R., Jensen F. C., Welsh R. M., Jr, Oldstone M. B. Lysis of RNA tumor viruses by human serum: direct antibody-independent triggering of the classical complement pathway. J Exp Med. 1976 Oct 1;144(4):970–984. doi: 10.1084/jem.144.4.970. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Corry J. M., Marshall W. C., Guthrie L. A., Peerless A. G., Johnston R. B., Jr Deficient activity of the alternative pathway of complement in beta thalassemia major. Am J Dis Child. 1981 Jun;135(6):529–531. doi: 10.1001/archpedi.1981.02130300029011. [DOI] [PubMed] [Google Scholar]
  10. Corry J. M., Polhill R. B., Jr, Edmonds S. R., Johnston R. B., Jr Activity of the alternative complement pathway after splenectomy: comparison to activity in sickle cell disease and hypogammaglobulinemia. J Pediatr. 1979 Dec;95(6):964–969. doi: 10.1016/s0022-3476(79)80284-x. [DOI] [PubMed] [Google Scholar]
  11. Craddock P. R., Fehr J., Dalmasso A. P., Brighan K. L., Jacob H. S. Hemodialysis leukopenia. Pulmonary vascular leukostasis resulting from complement activation by dialyzer cellophane membranes. J Clin Invest. 1977 May;59(5):879–888. doi: 10.1172/JCI108710. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Day N. K., Schreiber R. D., Götze O., Müller-Eberhard H. J. Reversible activation of proactivator (factor B) of the alternative pathway without cleavage of the molecule. Scand J Immunol. 1976;5(6-7):715–720. doi: 10.1111/j.1365-3083.1976.tb03021.x. [DOI] [PubMed] [Google Scholar]
  13. Dias Da Silva W., Kasatchkine M. D. Schistosoma mansoni: activation of the alternative pathway of human complement by schistosomula. Exp Parasitol. 1980 Oct;50(2):278–286. doi: 10.1016/0014-4894(80)90029-6. [DOI] [PubMed] [Google Scholar]
  14. Fearon D. T., Austen K. F. Activation of the alternative complement pathway due to resistance of zymosan-bound amplification convertase to endogenous regulatory mechanisms. Proc Natl Acad Sci U S A. 1977 Apr;74(4):1683–1687. doi: 10.1073/pnas.74.4.1683. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Fearon D. T., Austen K. F. Initiation of C3 cleavage in the alternative complement pathway. J Immunol. 1975 Nov;115(5):1357–1361. [PubMed] [Google Scholar]
  16. Fearon D. T., Ruddy S., Schur P. H., McCabe W. R. Activation of the properdin pathway of complement in patients with gram-negative of bacteremia. N Engl J Med. 1975 May 1;292(18):937–940. doi: 10.1056/NEJM197505012921802. [DOI] [PubMed] [Google Scholar]
  17. GINSBERG H. S., PILLEMER L., WEDGWOOD R. J. The properdin system and immunity. VI. The inactivation of Newcastle disease virus by the properdin system. J Exp Med. 1956 Nov 1;104(5):707–725. doi: 10.1084/jem.104.5.707. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Gewurz H., Shin H. S., Mergenhagen S. E. Interactions of the complement system with endotoxic lipopolysaccharide: consumption of each of the six terminal complement components. J Exp Med. 1968 Nov 1;128(5):1049–1057. doi: 10.1084/jem.128.5.1049. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Götze O., Müller-Eberhard H. J. The role of properdin in the alternate pathway of complement activation. J Exp Med. 1974 Jan 1;139(1):44–57. doi: 10.1084/jem.139.1.44. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. HINZ C. F., Jr, JORDAN W. S., Jr, PILLEMER L. The properdin system and immunity. IV. The hemolysis of erythrocytes from patients with paroxysmal nocturnal hemoglobinuria. J Clin Invest. 1956 May;35(5):453–457. doi: 10.1172/JCI103296. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Hammerschmidt D. E., Greenberg C. S., Yamada O., Craddock P. R., Jacob H. S. Cholesterol and atheroma lipids activate complement and stimulate granulocytes. A possible mechanism for amplification of ischemic injury in atherosclerotic states. J Lab Clin Med. 1981 Jul;98(1):68–77. [PubMed] [Google Scholar]
  22. Hammerschmidt D. E., Weaver L. J., Hudson L. D., Craddock P. R., Jacob H. S. Association of complement activation and elevated plasma-C5a with adult respiratory distress syndrome. Pathophysiological relevance and possible prognostic value. Lancet. 1980 May 3;1(8175):947–949. doi: 10.1016/s0140-6736(80)91403-8. [DOI] [PubMed] [Google Scholar]
  23. Heideman M. Complement activation in vitro induced by endotoxin and injured tissue. J Surg Res. 1979 Jun;26(6):670–673. doi: 10.1016/0022-4804(79)90063-5. [DOI] [PubMed] [Google Scholar]
  24. Hosea S., Brown E., Hammer C., Frank M. Role of complement activation in a model of adult respiratory distress syndrome. J Clin Invest. 1980 Aug;66(2):375–382. doi: 10.1172/JCI109866. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Ipp M. M., Minta J. O., Gelfand E. W. Disorders of the complement system in lipodystrophy. Clin Immunol Immunopathol. 1977 Mar;7(2):281–287. doi: 10.1016/0090-1229(77)90055-1. [DOI] [PubMed] [Google Scholar]
  26. Jordon R. E. Complement activation in bullous skin diseases. J Invest Dermatol. 1975 Jul;65(1):162–169. doi: 10.1111/1523-1747.ep12598113. [DOI] [PubMed] [Google Scholar]
  27. Kierszenbaum F., Weinman D. Antibody-independent activation of the alternative complement pathway in human serum by parasitic cells. Immunology. 1977 Feb;32(2):245–249. [PMC free article] [PubMed] [Google Scholar]
  28. LOWRY O. H., ROSEBROUGH N. J., FARR A. L., RANDALL R. J. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951 Nov;193(1):265–275. [PubMed] [Google Scholar]
  29. Lesavre P. H., Hugli T. E., Esser A. F., Müller-Eberhard H. J. The alternative pathway C3/C5 convertase: chemical basis of factor B activation. J Immunol. 1979 Aug;123(2):529–534. [PubMed] [Google Scholar]
  30. Macher A. M., Bennett J. E., Gadek J. E., Frank M. M. Complement depletion in cryptococcal sepsis. J Immunol. 1978 May;120(5):1686–1690. [PubMed] [Google Scholar]
  31. McCabe W. R. Serum complement levels in bacteremia due to gram-negative organisms. N Engl J Med. 1973 Jan 4;288(1):21–23. doi: 10.1056/NEJM197301042880105. [DOI] [PubMed] [Google Scholar]
  32. McLean R. H., Siegel N. J., Kashgarian M. Activation of the classic complement pathway in patients with the C3 nephritic factor. Nephron. 1980;25(2):57–64. doi: 10.1159/000181754. [DOI] [PubMed] [Google Scholar]
  33. McSharry J. J., Pickering R. J., Caliguiri L. A. Activation of the alternative complement pathway by enveloped viruses containing limited amounts of sialic acid. Virology. 1981 Oct 30;114(2):507–515. doi: 10.1016/0042-6822(81)90230-0. [DOI] [PubMed] [Google Scholar]
  34. Medicus R. G., Esser A. F., Fernandez H. N., Müller-Eberhard H. J. Native and activated properdin: interconvertibility and identity of amino- and carboxy-terminal sequences. J Immunol. 1980 Feb;124(2):602–606. [PubMed] [Google Scholar]
  35. Medicus R. G., Götze O., Müller-Eberhard H. J. Alternative pathway of complement: recruitment of precursor properdin by the labile C3/C5 convertase and the potentiation of the pathway. J Exp Med. 1976 Oct 1;144(4):1076–1093. doi: 10.1084/jem.144.4.1076. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Michael A. F., Westberg N. G., Fish A. J., Vernier R. L. Studies on chronic membranoproliferative glomerulonephritis with hypocomplementemia. J Exp Med. 1971 Sep 1;134(3 Pt 2):208s–227s. [PubMed] [Google Scholar]
  37. Müller-Eberhard H. J., Schreiber R. D. Molecular biology and chemistry of the alternative pathway of complement. Adv Immunol. 1980;29:1–53. doi: 10.1016/s0065-2776(08)60042-5. [DOI] [PubMed] [Google Scholar]
  38. Nathenson G., Miller M. E., Myers K. A., Stitzel A., Spitzers R. E. Decreased opsonic and chemotactic activities in sera of postburn patients and partial opsonic restoration with properdin and properdin convertase. Clin Immunol Immunopathol. 1978 Mar;9(3):269–276. doi: 10.1016/0090-1229(78)90098-3. [DOI] [PubMed] [Google Scholar]
  39. Nemerow G. R., Cooper N. R. Isolation of Epstein Barr-virus and studies of its neutralization by human IgG and complement. J Immunol. 1981 Jul;127(1):272–278. [PubMed] [Google Scholar]
  40. Nogueira N., Bianco C., Cohn Z. Studies on the selective lysis and purification of Trypanosoma cruzi. J Exp Med. 1975 Jul 1;142(1):224–229. doi: 10.1084/jem.142.1.224. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. PILLEMER L., BLUM L., LEPOW I. H., ROSS O. A., TODD E. W., WARDLAW A. C. The properdin system and immunity. I. Demonstration and isolation of a new serum protein, properdin, and its role in immune phenomena. Science. 1954 Aug 20;120(3112):279–285. doi: 10.1126/science.120.3112.279. [DOI] [PubMed] [Google Scholar]
  42. Pangburn M. K., Morrison D. C., Schreiber R. D., Müller-Eberhard H. J. Activation of the alternative complement pathway: recognition of surface structures on activators by bound C3b. J Immunol. 1980 Feb;124(2):977–982. [PubMed] [Google Scholar]
  43. Pangburn M. K., Müller-Eberhard H. J. Complement C3 convertase: cell surface restriction of beta1H control and generation of restriction on neuraminidase-treated cells. Proc Natl Acad Sci U S A. 1978 May;75(5):2416–2420. doi: 10.1073/pnas.75.5.2416. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Pangburn M. K., Schreiber R. D., Müller-Eberhard H. J. Formation of the initial C3 convertase of the alternative complement pathway. Acquisition of C3b-like activities by spontaneous hydrolysis of the putative thioester in native C3. J Exp Med. 1981 Sep 1;154(3):856–867. doi: 10.1084/jem.154.3.856. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Pangburn M. K., Schreiber R. D., Müller-Eberhard H. J. Human complement C3b inactivator: isolation, characterization, and demonstration of an absolute requirement for the serum protein beta1H for cleavage of C3b and C4b in solution. J Exp Med. 1977 Jul 1;146(1):257–270. doi: 10.1084/jem.146.1.257. [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. Perrin L. H., Lambert P. H., Miescher P. A. Properdin levels in systemic lupus erythematosus and membranoproleferative glomerulonephritis. Clin Exp Immunol. 1974 Apr;16(4):575–581. [PMC free article] [PubMed] [Google Scholar]
  47. Platts-Mills T. A., Ishizaka K. Activation of the alternate pathway of human complements by rabbit cells. J Immunol. 1974 Jul;113(1):348–358. [PubMed] [Google Scholar]
  48. Polhill R. B., Jr, Pruitt K. M., Johnston R. B., Jr Kinetic assessment of alternative complement pathway activity in a hemolytic system. I. Experimental and mathematical analyses. J Immunol. 1978 Jul;121(1):363–370. [PubMed] [Google Scholar]
  49. Ratnoff W. D., Pepple J. M., Winkelstein J. A. Activation of the alternative complement pathway by Histoplasma capsulatum. Infect Immun. 1980 Oct;30(1):147–149. doi: 10.1128/iai.30.1.147-149.1980. [DOI] [PMC free article] [PubMed] [Google Scholar]
  50. Rothfield N., Ross H. A., Minta J. O., Lepow I. H. Glomerular and dermal depostion of properdin in systemic lupus erythematosus. N Engl J Med. 1972 Oct 5;287(14):681–685. doi: 10.1056/NEJM197210052871402. [DOI] [PubMed] [Google Scholar]
  51. Schreiber R. D., Medicus R. G., Gïtze O., Müller-Eberhard H. J. Properdin- and nephritic factor-dependent C3 convertases: requirement of native C3 for enzyme formation and the function of bound C3b as properdin receptor. J Exp Med. 1975 Sep 1;142(3):760–772. doi: 10.1084/jem.142.3.760. [DOI] [PMC free article] [PubMed] [Google Scholar]
  52. Schreiber R. D., Pangburn M. K., Bjornson A. B., Brothers M. A., Müller-Eberhard H. J. The role of C3 fragments in endocytosis and extracellular cytotoxic reactions by polymorphonuclear leukocytes. Clin Immunol Immunopathol. 1982 May;23(2):335–357. doi: 10.1016/0090-1229(82)90119-2. [DOI] [PubMed] [Google Scholar]
  53. Schreiber R. D., Pangburn M. K., Lesavre P. H., Müller-Eberhard H. J. Initiation of the alternative pathway of complement: recognition of activators by bound C3b and assembly of the entire pathway from six isolated proteins. Proc Natl Acad Sci U S A. 1978 Aug;75(8):3948–3952. doi: 10.1073/pnas.75.8.3948. [DOI] [PMC free article] [PubMed] [Google Scholar]
  54. Schreiber R. D., Pangburn M. K., Medicus R. G., Müller-Eberhard H. J. Raji cell injury and subsequent lysis by the purified cytolytic alternative pathway of human complement. Clin Immunol Immunopathol. 1980 Mar;15(3):384–396. doi: 10.1016/0090-1229(80)90050-1. [DOI] [PubMed] [Google Scholar]
  55. Sissons J. G., Liebowitch J., Amos N., Peters D. K. Metabolism of the fifth component of complement, and its relation to metabolism of the third component, in patients with complement activation. J Clin Invest. 1977 Apr;59(4):704–715. doi: 10.1172/JCI108689. [DOI] [PMC free article] [PubMed] [Google Scholar]
  56. Sissons J. G., West R. J., Fallows J., Williams D. G., Boucher B. J., Amos N., Peters D. K. The complement abnormalities of lipodystrophy. N Engl J Med. 1976 Feb 26;294(9):461–465. doi: 10.1056/NEJM197602262940902. [DOI] [PubMed] [Google Scholar]
  57. Smith T. F., McIntosh K., Fishaut M., Henson P. M. Activation of complement by cells infected with respiratory syncytial virus. Infect Immun. 1981 Jul;33(1):43–48. doi: 10.1128/iai.33.1.43-48.1981. [DOI] [PMC free article] [PubMed] [Google Scholar]
  58. Tack B. D., Prahl J. W. Third component of human complement: purification from plasma and physicochemical characterization. Biochemistry. 1976 Oct 5;15(20):4513–4521. doi: 10.1021/bi00665a028. [DOI] [PubMed] [Google Scholar]
  59. Tenner A. J., Lesavre P. H., Cooper N. R. Purification and radiolabeling of human C1q. J Immunol. 1981 Aug;127(2):648–653. [PubMed] [Google Scholar]
  60. Winkelstein J. A., Tomasz A. Activation of the alternative complement pathway by pneumococcal cell wall teichoic acid. J Immunol. 1978 Jan;120(1):174–178. [PubMed] [Google Scholar]
  61. Ziccardi R. J. A new role for C-1-inhibitor in homeostasis: control of activation of the first component of human complement. J Immunol. 1982 Jun;128(6):2505–2508. [PubMed] [Google Scholar]
  62. Ziegler J. B., Rosen F. S., Alper C. A., Grupe W., Lepow I. H. Metabolism of properdin in normal subjects and patients with renal disease. J Clin Invest. 1975 Sep;56(3):761–767. doi: 10.1172/JCI108147. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES